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ABSTRACT

DIFFERENTIAL EXPRESSION AND FUNCTIONAL
CHARACTERIZATION OF ALPHA3 BETA2
NEURONAL NICOTINIC
ACETYLCHOLINE
RECEPTORS

John H. Mizukawa II
Department of Physiology and Developmental Biology
Master of Science

Neuronal nicotinic acetylcholine receptors (nAChRs) are expressed in both the
periperhal and central nervous systems, and are involved in pre-, post-, and non-synaptic
control of neuronal activation. In the brain, these receptors play an important role in a
variety of physiological processes such as cognition, development, learning, and memory
formation. Malfunction of these receptors have been implicated in neurodegenerative
diseases like Alzheimer’s disease (AD), schizophrenia, and Parkinson’s disease. To date,
17 different nAChR subunits, including α2-α7 and β2-β4, have been cloned that can form
homo- and/or hetero-pentameric ionotropic receptors. The unique combinations of
subunit pentamers manifest in distinct functional receptors. Using single-cell real-time

quantitative RT-PCR, we identified the individual expression rates and co-expression
rates of the different nAChR subunits in rat CA1 hippocampal interneurons in efforts to
characterize functional receptors involved in learning and memory. The two-way
combination of subunits with highest expression in hippocampal interneurons was α3β2.
Moreover, this combination was expressed in ratios near 1:3 or 3:1 α3 to β2 respectively.
To investigate the functionality of α3β2 receptors in different stoichiometries, we injected
human α3 and rat β2 subunit mRNA in 1:3, 1:1, and 3:1 ratios into Xenopus laevis
oocytes for expression. Two-electrode voltage clamp was then performed with the
application of different concentrations of ACh to produce full dose-response curves and
channel kinetics data. Distinct α3β2 functional channels were identified from the
different expression ratios based on significant differences in channel kinetics (i.e.- peak
current rise times, peak current decay times, steady state current in forced
desensitization) Dose-response curves produced no significant difference in EC50 values
in the different expression groups. However, there was a trend to greater agonist
sensitivity with increased α3 expression relative to β2. α3β2 receptors were further
characterized through forced desensitization of the receptors and generation of IV plots.
The findings from this study elucidate the neuronal nAChR subunit combinations that
form functional channels in hippocampal interneurons.
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INTRODUCTION
Acetylcholine (ACh) receptors in the mammalian nervous system have been
classified into the muscarinic (mAChR) and nicotinic (nAChR) subtypes based on the
ability of the agonists muscarine and nicotine to mimic the effects of ACh as a
neurotransmitter. Recently, investigation of nAChRs has sharply increased following
preclinical and clinical studies indicating that neuronal nAChRs may have a substantial
role in mediating cognition, reward and drug addiction, neuronal development, etc.
(Bourin, Ripoll et al. 2003; Gotti and Clementi 2004; Jensen, Frolund et al. 2005; Dani
JA 2007). Activation of nAChRs can modulate post synaptic fast excitatory
neurotransmission, pre-synaptic release of various neurotransmitters (not exclusively
ACh transmission), and nonsynaptic neuronal excitability (Figure 1b) (Gotti, Fornasari et
al. 1997; Newhouse, Potter et al. 1997; Jones, Sudweeks et al. 1999; Dani JA 2007).
There are three major cholinergic systems in the brain that innervate practically
all neural areas. One of these cholinergic systems originates in basal forebrain nuclei and
project into the cortex and hippocampus, effectively influencing cognitive functions like
learning, memory, attention, etc. Another major cholinergic subsystem originates from
neurons in the pedunculopontine tegmentum and the laterodorsal pontine tegmentum, and
innervates the thalamus, midbrain, caudal pons, and brain stem. The third cholinergic
system arises from striatal interneurons providing innervation to the striatum and
olfactory tubercle.(Bourin, Ripoll et al. 2003; Dani JA 2007). The effects of activation of
these three pathways can be quite extensive on many distinct brain functions.
Nicotinic acetylcholine receptors (nAChRs) are members of a large, structurally
homologous ligand-gated ion channel superfamily together with GABAA, glycine, and 5-
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HT3 serotonin receptors (Ortells 1995; Jensen, Frolund et al. 2005; Dani JA 2007).
Located in a variety of tissues, nAChRs play a functional role in the autonomic nervous
system, neuromuscular junction, and brain in vertebrates (Lopez-Hernandez, SanchezPadilla et al. 2004; Pimlott and Wyper. 2004; Dani JA 2007). Like every member of the
ligand-gated ion channel family, the nAChR is a transmembrane receptor protein
consisting of five polypeptide subunits arranged around a “pseudo-axis of symmetry”
(Bourin, Ripoll et al. 2003). Each subunit has a large extracellular N-terminal segment,
four transmembrane domains, and a small extracellular C-terminal tail (Changeux,
Bertrand et al. 1998). The second transmembrane region of each subunit lines the nonspecific cation pore and is highly conserved between subunits (Jensen, Frolund et al.
2005). The same subunits also share high homology between species (over 80%
conserved amino acid sequences between vertebrate species) (Changeux and Edelstein
2005). The ACh binding site is at the interface between two subunits (one alpha and one
beta, with the exception of α7 homomeric channels) in the N-terminal extracellular region
(Figures 1a and 2). nAChRs also contain a rather large intracellular amino acid loop
between the third and fourth transmembrane regions (Figure 1a Right). This loop is
susceptible to modification by intracellular second messenger cascades.
To date, seventeen nAChR subunits have been cloned and identified (α1-10, β1-4,
γ, δ, and ε) (Curtis L. 2002; Jensen, Frolund et al. 2005; Gotti, Zoli et al. 2006; Dani JA
2007). The neuronal nAChR subunits include α2-10 and β2-4, of which the majority
have been identified to be natively expressed in the central (CNS) and peripheral (PNS)
nervous systems (the α8 subunit has only been found in chickens; the α9 and α10
subunits show limited expression in the cochlea) (Jensen, Frolund et al. 2005; Dani JA
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2007). The physiological, biophysical, and pharmacological properties of nAChRs in the
brain are determined by the pentameric co-assembly of these different subunits.
Activation of different subtypes of nAChRs (due to unique pentameric assemblages) can
differentially modulate, not only neurotransmitter release and synaptic plasticity, but also
calcium-dependent cellular events that include activation and modulation of other ion
channels, excitability, secretion, motility and migration, gene expression, and cell
differentiation and survival (Sher, Chen et al. 2004). These effects can be caused by
distinct properties of calcium conductance through different nAChRs. For example, it
has been demonstrated that the expression of the α5 subunit in α3β2 and α3β4 containing
receptors causes an increase in Ca++ permeability (Yu and Role 1998).
Although many subunit combinations have been identified in the CNS, the most
commonly investigated mammalian neuronal nAChRs contain the α7 or α4β2 subunits
which form homomeric or heteromeric complexes, respectively (Changeux, Bertrand et
al. 1998). It is primarily asserted that the majority of brain nAChRs with a high affinity
for agonist contain the α4 and β2 subunits, whereas α3 and β4 subunit-containing
nAChRs are highly expressed in the peripheral nervous system (Jensen, Frolund et al.
2005). It is also commonly believed that the α4β2 and α3β4 receptor subtypes are
natively expressed in a stoichiometric ratio of two α subunits to three β subunits arranged
in the specific sequence of αβαββ (Anand R 1991; Boorman, Groot-Kormelink et al.
2000; Jensen, Frolund et al. 2005). However, recent studies have shown that different
stoichiometric expressions of the α:β subunit ratio will result in distinct receptor
properties (i.e., affinity for agonists/antagonists, current kinetics, etc.). They have also
shown that a different stoichiometric expression of the α4β2 receptor subtype can be
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forced to deviate from the 2α:3β expression ratio simply by changing the subunit
transfection ratios (Zwart and Vijverberg 1998; Nelson, Kuryatov et al. 2003; LopezHernandez, Sanchez-Padilla et al. 2004).
The involvement of brain nAChRs in a variety of cognitive and behavioral
systems is sufficiently supported by nAChR knockout studies, which imply that nAChRs
are involved with neurodegenerative disorders including Alzheimers disease (AD),
schizophrenia, epilepsy, autism, and in aging (Figure 3) (Jones, Sudweeks et al. 1999;
Court 2001; Woodruff-Pak DS 2002; Bourin, Ripoll et al. 2003; Dani JA 2007).
Revealed by behavioral and electrophysiological studies, evidence implicates the
nicotinic system is linked in AD and the α7 receptor subtypes are essentially presynaptic,
while the α4/β2 receptor subtypes are pre- and postsynaptic (Gotti, Fornasari et al. 1997).
AD is characterized by accumulation of senile plaques, mainly composed of the betaamyloid peptide (Aβ). Even though the exact causes of AD are unknown, different
pathogenesis hypotheses implicating nAChRs made up of α7 subunits have been
proposed, with the receptors exerting a direct or indirect action on the mechanism of Aβ
toxicity. The application of Aβ has recently been shown to impede nAChR function in
rat hippocampal neurons (Pettit, Shao et al. 2001).
Since hippocampal interneurons express various functional combinations of
nAChR subtypes (Jones and Yakel 1997; Frazier, Rollins et al. 1998; Ji 2000; Sudweeks
and Yakel 2000) drugs might be designed to interact selectively with a specific nAChR
subtype and therefore provide different therapeutic opportunities. Thus, drug treatment
may contribute to specific physiological and behavioral functions without causing
adverse or undesired side effects due to interactions with other nAChR subtypes located
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elsewhere in the nervous system (Levin 2002). In order to fully understand the
biophysical and pharmacological properties of functional nAChRs in the brain, we need
to identify the underlying subunit combinations expressed in different areas of the brain.
Co-expression of nAChR subunits into non-native cell lines is a technique that is
commonly used to facilitate the characterization of nAChR function. Successful
heterologous expression of nAChRs has been achieved using human embryonic kidney(HEK-) 293 cells and Xenopus laevis oocytes. For example, several studies examining
the function of heterologously expressed nAChRs in the Xenopus cell system reveal a
diverse pharmacological profile in receptors containing monomeric combinations of α7
(Khiroug, Harkness et al. 2002), and dimer combinations of α2, α3, α4, or α7 in
combination with β2 or β4 (Vibat 1995; Elliott, Ellis et al. 1996; Fenster 1997; Khiroug,
Harkness et al. 2002). Xenopus laevis oocytes also showed no nicotinic response to
acetylcholine application unless injected with exogenous nAChR subunit mRNA
(Deneris, Boulter et al. 1989). For these studies we injected Xenopus laevis oocytes with
nAChR subunit mRNA to study the functional properties of α3β2 neuronal nAChRs. The
subunit mRNA ratios we used were based on those identified in native rat hippocampal
interneurons using quantitative single-cell RT-PCR. Our results provide a
characterization of how expression of these two subunits in different ratios can form
distinct subtypes of functional ion channels.
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MATERIALS AND METHODS
Slice Preparation
The PCR related protocol was followed as described in Burgon 2006. To obtain
the interneurons, coronal brain slices (either 300 or 350 µm thick) were made from 8 to
23 day-old Wistar rats using a Vibratome 1000-Plus (Pelco, Redding, CA). The slices
were cut in ice-cold oxygenated (95% O2, 5% CO2) artificial cerebro-spinal fluid (ACSF
in mM: 124 NaCl, 2 KCl, 1 Na H2PO4, 26 NaHCO3, 11 Glucose, 2 CaCl2, 1 MgSO4) and
placed in room-temperature oxygenated ACSF for at least 30 minutes prior to placing in
microscope recording chamber.
Individual hippocampal interneurons from the CA1 stratum oriens and stratum
radiatum (Figure 4) were visually identified using an upright microscope with infrared
light, and aspirated into a standard whole-cell patch-clamp pipette (Borosilicate
capillaries, Harvard Apparatus, Kent, England) containing 5 µL Intracellular Fluid (ICF
in mM: 10 MgCl2, 0.1 CaCl2, 1 EGTA, 10 HEPES, 135 K-Gluconate, Na-2 ATP).
Electrophysiology of Wistar Rat CA1 Hippocampal Interneurons
A whole-cell patch clamp of the interneuron was obtained in voltage-clamp mode
prior to cytoplasm aspiration. Interneuron membrane potentials were held at -70 mV.
Primers and Probes
Primers and probes were purchased from Invitrogen (Carlsbad CA). The primers
and probes were designed using either Vector NTI version 7.0 (Invitrogen) or Primer
Express version 2.0 (ABI Prism, Foster City CA) software.
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RT Reaction
A cDNA library representing each interneuron was made by running a reverse
transcription reaction using BIORAD (Hercules CA) iScript cDNA Synthesis Kit with a
final volume of 10 µL.
Multplex Reaction and Real-time Quantitative PCR
A multiplex PCR reaction was run (15 cycles) for each aspirated interneuron
using all neuronal nAChR primers as well as primers for 18s rRNA with a final volume
of 75 µl. The multiplex reaction was run using reagents by Invitrogen including
Platinum® Taq DNA Polymerase and PCR nucleotides (10 mM). A second round of
PCR was run (60 cycles) for each specific target (18s, α2-α7, and β2-β4) using an ABI
7000 Sequence Detection System (Applied Biosystems, Foster City, CA) utilizing
BIORAD iTaq Supermix with ROX. Cycle threshold values for each target were
compared to the reference gene 18s for analysis (more in Real-Time Analysis).
Standard curves (efficiency tests) for each cDNA target were developed by
running 60-cycle real-time quantitative PCR assays on positive controls (rat whole-brain
homogenate) for six known concentrations (100, 33.3, 10, 3.33, 1, 0.333 ng cDNA/µL).
Upstream (primer +) and downstream (primer -) primer concentrations were adjusted to
optimize amplification as reported previously. The efficiency of the amplification
reaction is calculated using the slope of the log(concentration) vs. CT plot. The formula
for PCR efficiency = 10

(-1/slope)

– 1. Reaction efficiencies were run in triplicate and the

amplification efficiencies were compared using ANOVA to determine if there were
significant differences between any of the primer/probe sets (18s, α2-α7, and β2-β4).
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Real-Time Analysis
After running the real-time quantitative PCR on hippocampal interneurons, raw
fluorescence (Delta Rn) values across 60 cycles were curve-fit using a Boltzmann
Sigmoidal function with an output of either 2000 or 4000 data points in the new curve
using Prism ver. 4.03 (GraphPad Software, San Diego CA). The second derivative graph
for the curve-fit data was then determined, also using the GraphPad software. The cycle
threshold (CT) value used for quantitative analysis was determined by finding the cycle
number (along the x-axis) corresponding to the maximum Delta Rn value (along the yaxis), as described previously (Burgon 2006).
Primer Efficiencies Analysis
Triplicate reactions of each cDNA target were averaged and a linear regression
equation was calculated (SLOPE function, Microsoft Excel, Microsoft Office 2003,
Redmond WA) of the CT values corresponding to the six known concentrations (100,
33.3, 10, 3.33, 1, 0.333 ng cDNA/µL) in the standard curve primer efficiency tests. The
PCR efficiency was then determined by incorporating the slope of the linear equation
using the formula described above (see Multiplex Reaction and Real-Time Quantitative
PCR).
Analysis of mRNA Expression in Rat Hippocampal Interneurons
For comparison between cDNA targets, fold expression values from the triplicate
CT averages were calculated as reported previously, but compared to the CT value
corresponding to the lowest level of cDNA detection (Livak and Schmittgen 2001).
Significance between relative levels of mRNA expression was calculated by comparing
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mean fold expression values using a Mann-Whitney test (calculated using InStat ver.
3.05, GraphPad software, San Diego CA).
Plasmid DNA Preparation
The human α3 subunit and rat β2 genes were inserted into the pCMV6-XL4
(Origene Technologies, Rockville MD) and the pcDNA 3.1 (Invitrogen, Carlsbad CA)
plasmids, respectively, using a digestion and ligation protocol from New England Biolabs
(Ipswich MA) and Bioline (London UK), respectively. All plasmids were grown up
using a transformation protocol by Yeastern Biotech (Taipei TW) and carried out in
accordance with its guidelines. A plasmid isolation and purification protocol was
followed using the HiSpeed® plasmid purification kit by QIAGEN Inc. (Valencia CA).
Xenopus Oocyte Isolation
Female Xenopus laevis frogs were provided by the National Institute of 30
minutes until notably unresponsive. They were then anesthetized by immersion in a
solution containing 0.1% ethylmetaaminobenzoate (MS-222; Sigma) for 20 minutes. The
frogs were sacrificed in accordance with guidelines approved by the NIEHS Animal Care
and Use Committee by severing the spinal cord. Oocytes were dissected and
defolliculated by treatment with collagenase B (Roche Diagnostics, Basel Switzerland, 2
mg/mL) and trypsin inhibitor (GIBCO, Invitrogen, Carlsbad CA, 1 mg/mL) in an
calcium-free OR-2 solution [Ca2+-free OR-2 in mM: 82.5 NaCl, 2 KCl, 1 MgCl2[6H2O],
5 HEPES (pH 7.5-7.6)] for 2 hours. The cells were then rinsed in a BSA-enriched Ca2+free OR-2 solution (same as above with 1mg/mL BSA). The oocytes were incubated at
18oC gently rotating at roughly 100 rpm in an OR-2 solution containing Ca2+ [OR-2 with
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Ca2+ in mM: 82.5 NaCl, 2.5 KCl, 1.0 Na2HPO4, 3.009 NaOH, 5 HEPES, 1.0 CaCl2, 1.0
MgCl2, 2.5 Pyruvic Acid, 0.05 mg/mL Gentamycin Sulfate (pH 7.5-7.6)].
RNA Preparation and Expression in Oocytes
Plasmid DNA containing genes for the human α3 and rat β2 nAChR subunits
were linearized by restriction digest using XhoI and NotI, respectively (New England
BioLabs). mRNA was then transcribed and capped on the 5’ end using the mMessage
Machine kit (Ambion, ABI, Foster City CA) according to the protocol provided by the
manufacturer. Each oocyte was injected with a total of 20 ng of mRNA (5 ng of α3: 15
ng β2 for the 1:3 expression, 10 ng of α3:10 ng β2 for the 1:1 expression, and 15 ng α3: 5
ng β2 for the 3:1 expression) in a total volume of 50 nL. Injection of 50 nL allowed for
visual confirmation of a successful injection. Recordings were performed 2-5 days postinjection.
Electrophysiological Recordings
Current recordings were obtained by performing two-electrode voltage-clamp
(Figure 5) on the mRNA injected oocytes with a Geneclamp 500 and pCLAMP 8
software (Axon Instruments, Molecular Devices, Sunnyvale CA). Traces were filtered at
2 kHz and sampled at 5 kHz with a holding potential of -60 mV. Electrodes containing 3
M KCl were formed from borosilicate glass capillaries (Harvard Apparatus, Kent,
England) and had resistances of less than 1 MΩ. ACh solutions (1 µM, 10 µM, 100 µM,
300 µM, 1mM, 10 mM, 30 mM) were freshly prepared from a frozen stock solution or
powder diluted in an ECF-like bath solution containing 96 mM NaCl, 2 mM KCl, 1.8
mM CaCl2, 1 mM MgCl2, and 5 mM HEPES (pH 7.4). Four different concentrations of
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ACh were placed into four separate tubes feeding into the same synthetic quartz
application pin (0.7 mm id) operated by a computer-controlled valve.
Dose-Response Recordings
Currents elicited from different concentrations of ACh determined that 10 mM
ACh resulted in a maximal peak current. A recovery period of 2 minutes following a 1
second 30 mM ACh application was required for current to return to baseline with the
flow rate of bath solution replacement approximately 3 mL/min. Therefore, ACh was
applied every 2 minutes and allowed to completely wash away before the subsequent
application. Because there were only four tubes available for application of different
ACh concentrations, the current elicited from 3 different doses of acetylcholine were
compared to the maximal response of a 1s 10mM application on that same cell. All
currents from every dose of ACh were normalized to the peak current from the 10 mM
ACh application (Figure 7).
IV Plots and Forced Desensitization
IV plots were obtained by measuring the maximum current elicited from a 1s 10
mM application of ACh at six holding potentials from -60 to +40 mV (-60 mV, -40 mV, 20 mV, 0 mV, 20 mV, and 40 mV) (Figure 8). ACh application occurred in 2 minute
intervals as described above. Forced desensitization curves were produced by
continuously applying 300 µM ACh for 55 seconds (Figure 10).
Data Analysis
Peak currents, 10-90% rise times, 90-10% decay times, curve fitting, and Tau
calculations were measured and analyzed using Clampfit (Axon Instruments) and
Microsoft Excel (Microsoft Office 2003, Redmond WA). Tests of significance using a
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two-tailed t-test were also performed in Microsoft Excel. Only P values less than 0.05
were considered significant. GraphPad 4.0 (GraphPad software, Prism) was used to
graph the dose-response curves and calculate the EC50’s from each curve. IV plots were
graphed and curve fitted using Microsoft Excel. Reversal Potentials for the receptors
were calculated by solving the best curve fit equation for y=0 (Figure 9).
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RESULTS
Neuronal nAChR Subunit mRNA expression in rat CA1 hippocampal interneurons
Rat CA1 hippocampal interneurons from the stratum radiatum and stratum oriens
were individually aspirated and analyzed for their level of expression of the α2-α10 and
β2-β4 neuronal nAChR subunits compared to 18s rRNA expression. Of the 89
interneurons analyzed, 88.8% (n=79) expressed the mRNA of at least one nAChR
subunit. In the 79 cells that expressed nAChR subunits, the two-way combination of
nAChR subunits with the highest co-expression rate was found to be α3β2 (43.0%,
n=34). By excluding two-way combinations of subunits that could not make functional
channels (i.e.- α subunits paired with α subunits, β subunits paired with β subunits, α5
with any other subunit, and β3 with any other subunit) the co-expression rates of the
remaining subunits decreased as follows: 38% α7β2, 33% α3β4, 27% α4β2, 24% α2β2,
22% α7β4, 20% α2β4, 15% α4β4 (Figure 6).
The α3 subunit was expressed in 59.5% (n=47) of the 79 nAChR expressing
interneurons. Coincidentally, the individual β2 subunit expression rate was also 59.5%
(n=47). The product of these individual expression rates gives us an expected coexpression rate of 35.4%, which is ~7.6% lower than the 43.0% co-expression we
observed. Interestingly, of the 47 cells that expressed the α3 subunit, 72.3% (n=34) also
expressed the β2 subunit. Likewise, of the 47 cells that expressed the β2 subunit, 72.3%
(n=34) also expressed the α3 subunit. This as well suggests the propensity for α3 and β2
subunits to co-express in CA1 hippocampal interneurons. Furthermore, while unique
subunit combinations were found in 47.2% (n=42) of the hippocampal interneurons
sampled, the most common single cell combinations were found to both contain α3 and
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β2 subunits (α3α4α5α7β2 and α3α5β2β3β4 were expressed in 4 cells each). The relative
fold expression of α3 compared to β2 (and vice versa) in individual interneurons was
calculated in order to hypothesize the stoichiometric expression ratio of the α3 and β2
subunits. The α3 subunit demonstrated a 2.5 fold expression over β2 in cells where the
α3 subunit was expressed more than the β2 subunit (n=15). In cells that expressed more
β2 than α3, the β2 subunit showed a 3.3 fold expression over α3 (n=19). These data
convinced us that the α3β2 nAChR subunit combination should be investigated in a 1:3
or 3:1 expression ratio in order to best mimic our observations in native rat CA1
hippocampal interneurons.
10%-90% Rise Times
Two-electrode voltage clamp was performed on Xenopus laevis oocytes injected
with α3 and β2 subunit mRNA in 1:3, 1:1, and 3:1 ratios in the presence of the agonist
ACh. The time required for the current to rise from 10% to 90% of the maximum current
elicited from a 1s application of 10 mM ACh was calculated in Clampfit version 9.2
(Molecular Devices, Sunnyvale CA) and potential statistical significance was analyzed in
Microsoft Excel (Microsoft Office 2003, Redmond WA). Cells injected with α3 and β2
mRNA in a 1:3 ratio demonstrated an average 10-90% rise time of 221.76 ms ± 47.79.
The oocytes injected with α3 and β2 mRNA in a 1:1 and 3:1 ratio produced faster
average 10-90% rise times of 143.95 ms ± 30.27, and 98.14 ms ± 9.52, respectively. A
two-tailed t-test performed for the two groups of physiological pertinence [the 1:3 (n=40)
and 3:1 (n=43) expression groups] revealed a significant difference in 10-90% rise times
(P =0.010) (Tables 1a & b, Figure 12). ANOVA was also performed (InStat, GraphPad
Software) on the three different expression groups. We found no significant difference of
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10-90% rise times between the 1:3 and 1:1 expression groups, nor between the 3:1 and
1:1 expression groups. ANOVA did confirm the significant difference between the 1:3
and 3:1 expression groups. ANOVA failed to demonstrate any significant differences in
comparisons involving the 1:1 expression group for any of the parameters tested.
Therefore, a two-tailed t-test was performed to indicate significant differences between
the 1:3 and the 3:1 expression groups for all parameters tested, since these were the two
groups of physiological relevance.
Reversal Potentials
IV plots were produced for each of the expression groups (1:3, 1:1, and 3:1 α3β2)
by measuring the peak current elicited from a 1s application of 10 mM ACh at each of six
holding potentials (-60 mV, -40 mV, -20 mV, 0 mV, 20 mV, 40 mV). The IV plots for
α3β2 nAChRs showed considerable inward current rectification (see Figure 8 for
example of IV plot). Best fit curves (R2>0.999) for the IV plots were calculated in
Microsoft Excel and the curve fit equations were solved (y=0) to find the reversal
potentials. The cells injected with α3β2 mRNA in a 1:3 ratio (n=3) showed Nernst
potentials averaging -24.65 mV ± 3.63, while the 1:1 expression group (n=4) and the 3:1
expression group (n=5) produced reversal potentials of -17.58 mV ± 1.34 and -16.91 mV
± 1.99, respectively. A two-tailed t-test performed for the two groups of physiological
pertinence (1:3 and 3:1 expression groups) showed no significant difference between
their reversal potentials (P=0.0845) (Tables 2a & b, Figure 13).
Steady State Current Compared to Peak Current with Extended Agonist Application
(Forced Desensitization)
During the forced desensitization of the α3β2 nAChRs due to a 55s application of
300 µM ACh, we observed a steady state current above the resting baseline (see Figure 9
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for example). Such a prolonged application and high concentration of ACh would
typically evoke a classical agonist-bound desensitized state of the receptor (Giniatullin,
Nistri et al. 2005; Gay and Yakel 2007), but we see a low, persistent, steady-state current
during the end of the 55s application. The steady-state current at 55 seconds was
measured from baseline, calculated into a percent of the peak current, and compared
between the different expression groups (1:3, 1:1, 3:1). The average steady-state current
during forced desensitization for cells injected with α3 and β2 mRNA in a 1:3 ratio (n=2)
was 37.39% ± 0.02 of the initial peak current. The 1:1 expression group (n=4) shared a
similar high steady-state current at 41.41% ± 0.09 of the peak current. The 3:1
expression group (n=6) showed a much lower average steady-state current in forced
desensitization at 25.29% ± 0.03. A two-tailed t-test on the means of the steady-state
currents in the 1:3 and 3:1 expression groups showed that they are significantly different
(P=0.0347) (Tables 3a & b, Figure 14).
# of Exponents Used in Curve Fit
The decay curve in forced desensitization showed a slightly irregular pattern,
especially at ~7s after the peak (Figure 10). The rebound effect after the 55s application
was similar to that seen in human α3β2 currents referenced by Jensen et al. (Jensen,
Frolund et al. 2005). Analysis of the decay curve from the peak to the steady state
current (excluding the rebound effect at 55s) in forced desensitization was performed in
Clampfit to form a best fit curve. The lowest number of exponents used to fit the decay
curve with the highest correlation (R2) was compared between the 1:3, 1:1, and 3:1 α3β2
expression groups. The average number of exponents used to best fit the forced
desensitization decay curve in the 1:3 expression group (n=2) was 1.33 ± 0.33. In the 3:1
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expression group (n=6), the average number of exponents used to fit the forced
desensitization curve was 3.33 ± 0.80. A two-tailed t-test showed no significant
difference between the two groups (P=0.138). The 1:1 expression group (n=4) required
an average of 2.5 exponents ± 0.87 (Tables 4a & b, Figure 15).
90%-10% Decay Time
The time required for the peak current to decay from 90% to 10% (using the
steady-state current as baseline) in forced desensitization from a 55s application of 300
µM ACh was calculated in Clampfit. The 90-10% decay time in cells expressing the 1:3
α3β2 ratio (n=2) averaged 20074.33 ms ± 5026.72. The cells expressing α3β2 in a 1:1
ratio (n=4) produced an average forced desensitization 90-10% decay time of 16647.24
ms ± 674.87. The 3:1 α3β2 expression group (n=6) produced an average forced
desensitization 90-10% decay time of 13014.86 ms ± 717.14. This was significantly
different from the average decay time in cells expressing the 1:3 ratio of α3β2 subunits,
according to a two-tailed t-test (P=0.040) (Tables 5a & b, Figure 16).
Decay Constants in Forced Desensitization
The decay constant (tau) was calculated in Clampfit for each component of the
forced desensitization curves elicited from a 55s application of 300 µM ACh. The largest
tau for each of the forced desensitization curves was averaged for each expression group
for statistical analysis. The average decay taus for the 1:3, 1:1, and 3:1 α3β2 expression
groups were 10687.23 ms ± 76.63, 11823.91 ms ± 2525.49, and 11368.12 ms ± 3317.60,
respectively (Table 6a). A two-tailed t-test revealed that there was no significant
difference between the average taus for the 1:3 and 3:1 expression groups (P=0.914)
(Table 6b, Figure 17).
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Dose-Response Curves
It has been previously demonstrated that differential stoichiometric expression of
heteromeric αβ nAChRs can greatly affect receptor sensitivity to agonist (Zwart and
Vijverberg 1998; Nelson, Kuryatov et al. 2003; Lopez-Hernandez, Sanchez-Padilla et al.
2004; Moroni, Zwart et al. 2006). Full dose-response curves were compiled at ACh
concentrations of 1 µM, 10 µM, 100 µM, 300 µM, 1 mM, and 10 mM (Figure 11a).
Current responses were also elicited from 1s applications of 30 mM ACh to verify that
the maximally effective concentration was 10 mM ACh for each different expression
group (1:3, 1:1, and 3:1). The average % of the peak current elicited from a 1s
application of 30 mM ACh was 96.09% for the 1:3 expression group (n=9), 75.77% for
the 1:1 expression group (n=9), and 97.97% for the 3:1 expression group (n=12) (Figure
11b). The 30 mM data were not included in the dose-response curves for the sake of
maximally fitting the curve to the data points.
Confident that a 1s application of 10mM ACh produced the maximal response, all
other responses to the different ACh concentrations could be normalized to the peak
current from the application of 10 mM ACh on the same cell. The average of 3 replicates
at each ACh concentration in the dose-response curve was taken to compile a list of 45
averages for the 1:3 dose-response curve, 40 averages for the 1:1 dose-response curve,
and 45 averages for the 3:1 dose-response curve. The average % of peak current at each
ACh concentration was then taken from the averages of the replicates to provide 6 points
for the dose-response curves in each of the expression groups. Dose-response analysis
and graphing was performed on Prism ver. 4.03 (GraphPad Software, San Diego CA).
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The EC50 of each dose-response curve was calculated in Prism. Cells injected with α3β2
mRNA in a 1:3 ratio showed the highest sensitivity to ACh with an EC50 of 129.5 µM
ACh. The EC50 of the 1:1 α3β2 expression group increased 60.2 µM to 189.7 µM ACh.
The 3:1 expression group showed the lowest sensitivity to ACh with an EC50 of 245.5
µM. While a t-test showed no significant difference between the EC50 values of the 1:3
and 3:1 expression groups (P=0.4656), it is interesting to note that the pattern of receptor
sensitivity decreases in almost even increments from 1:3 to 1:1 to 3:1. For a summary of
all results, see the consolidated results table (Table 7).
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TABLES AND FIGURES

Figure 1a. Pentameric assembly of nAChR subunits (Left). General structure of an individual
nAChR subunit.
b. Pre-, post-, and non-synaptic location of nAChRs (illustration from Laviolette and van der Kooy
2004).
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Figure 2. Ion pore of the Torpedo nAChR. Transmembrane regions for one of the five subunits
marked M1-M4. Opening of the ion channel: cross-sections of the closed and open ion channels in
the middle of the membrane.(Jensen, Frolund et al. 2005)
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Figure 3. Distribution of nAChR subunits in the rodent brain. The nAChR subunits predominantly
expressed in selected CNS regions are shown, and the nAChRs proposed as potential therapeutic
targets in various disorders are indicated: Hc, hippocampus; Ht, hypothalamus; VTA, ventral
tegmental area; SN, substantia nigra; Olf, olfactory region; Am, amygdala; LC, locus coeruleus.
(Jensen, Frolund et al. 2005)
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Rat Hippocampus
Stratum Oriens
Stratum Pyramidale
Stratum Radiatum

CA1

CA3

Figure 4. Rat hippocampal slice showing the rough anatomy of the hippocampus. Arrows indicate
areas where interneurons were aspirated for PCR analysis (Photo from (Swanson 1998).
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Figure 5. Example of a two-electrode voltage clamp setup for current recordings on Xenopus
oocytes (Photo by: Mizukawa 2008).
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Neuronal nAChR Subunit Co-Expression in Individual Interneurons
43%

of Cells Co-expressed α3 and β2

38%

of Cells Co-expressed α7 and β2

33%

of Cells Co-expressed α3 and β4

27%

of Cells Co-expressed α4 and β2

24%

of Cells Co-expressed α2 and β2

22%

of Cells Co-expressed α7 and β4

20%

of Cells Co-expressed α2 and β4

15%

of Cells Co-expressed α4 and β4

Figure 6. The most common mRNA combinations of two neuronal nAChR subunits observed in
individual hippocampal CA1 interneurons using single-cell quantitative RT-PCR (n=79).
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Dose-Response Currents
1000

1s ACh App.
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nA
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-7000
-8000
0
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70

80

Seconds
Figure 7. Example of currents in the dose-response protocol. Currents seen above were elicited from
3 consecutive 1s applications of 100 µM, 1 mM, 10 mM, and 30 mM ACh waiting 2 minutes between
ACh applications.

26

Current Elicited from 10 mM ACh Application at 20 mV steps
(from -60 to +40 mV)
1500
1s- 10 mM ACh App.

1000
500
0

nA

-500
-1000
-1500
-2000
-2500
-3000
-3500
1

1.5

2

seconds

2.5

3

3.5

Figure 8. Example of currents in the IV protocol. Currents seen above were in response to a 1s
application of 10 mM ACh at holding potentials of -60, -40, -20, 0, 20, 40 mV waiting 2 minutes
between ACh applications.
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IV Plot
500

0
-80

-60

-40

-20

0

20

40

60

-500
currrent (nA)

R2 = 0.9997
-1000

-1500

-2000

-2500

-3000
holding potential (mV)

3:1
Figure 9. IV plot showing rectification of a 3:1 α3β2 nAChR in Xenopus oocytes with holding
potentials of -60, -40, -20, 0, 20, 40 mV. Each current was elicited from a 1s application of 10 mM
ACh.
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Forced Desensitization Following Extended ACh Application
500

55s- 300 µM ACh App

0
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-1000
-1500
-2000
-2500
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20

30
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50

60

seconds
Figure 10. Example of current in forced desensitization. 300 µM ACh was applied constantly over a
55s period to force the receptor into a desensitized state.
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proportion of peak current

11a.

1.1
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0

1:1 α3β2 dose response
1:3 α3β2 dose response
3:1 α3β2 dose response

-7

-6

-5

-4

-3

-2

-1

log [ACh]
b.
EC50
R²
Total number of values

1:3
0.0001295
0.9154
45

1:1
0.0001897
0.9218
40

3:1
0.0002455
0.9206
45

Figure 11a. Dose-response curves for (from left to right) 1:3, 1:1, and 3:1 α3β2 nAChRs. Six
concentrations (1 µM, 10 µM, 100 µM, 300 µM, 1 mM, 10 mM) of ACh were normalized to the peak
currents elicited from a 1s application of 10 mM ACh. Points for the dose-response curves were
taken from the averages of the % of peak at each given dose for each respective stoichiometric
expression ratio.
b. EC50 values for each of the three dose-response curves. R2 values for the curve fit of the doseresponses are also listed with the number of values used to calculate each curve.

30

10-90% Rise Times
1:3
Mean (msec)

3:1

1:1

222

98

144

48

10

30

Median

144

87

91

Standard Deviation

302

62

189

91364

3900

35726

1312

324

1022

Minimum

39

32

36

Maximum

1351

357

1058

40

43

39

Standard Error

Sample Variance
Range

Count

Table 1a. Column statistics for the rise times from 10% to 90% of
the peak current elicited from a 1s application of 10 mM ACh.

t-Test: Two-Sample Assuming Equal Variances
1:3
3:1
Mean (msec)
222
98
Variance
91364
3900
Observations
40
43
Pooled Variance
46013
Hypothesized Mean Difference
0
Df
81
t Stat
3
P(T<=t) one-tail
0.005
t Critical one-tail
1.66
P(T<=t) two-tail
0.010 significant
t Critical two-tail
1.99
Table 1b. Two-tailed t-test for difference in the means of the 1090% rise times of the 1:3 and 3:1 α3 β2 groups. ( significance =
P<0.05).
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Mean 10-90% Rise Times (ms)
300

*
250

Time (ms)

200

150

100

50

0
1:3

3:1

1:1

Figure 12. Average of the 10%-90% rise times elicited from a 1s application of 10 mM ACh (*
indicates P<.01 significance, two-tailed t-test).
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Reversal Potentials
Mean (mV)
Standard Error
Median
Standard
Deviation
Sample Variance
Range
Minimum
Maximum
Sum
Count

1:3
-25
4
-24

1:1
-18
1
-17

3:1
-17
2
-17

6
40
12
-32
-19
-74
3

3
7
6
-21
-16
-70
4

4
20
12
-22
-11
-85
5

Table 2a. Column statistics for the reversal potentials from
current elicited from a 1s application of 10 mM ACh at mV steps of
-60, -40, -20, 0, 20, 40 mV.

t-Test: Two-Sample Assuming Equal Variances
1:3
3:1
Mean (mV)
-25
-17
Variance
40
20
Observations
3
5
Pooled Variance
26
Hypothesized Mean Difference
0
Df
6
t Stat
2
P(T<=t) one-tail
0.04
t Critical one-tail
1.9
not
P(T<=t) two-tail
0.09 sig.
t Critical two-tail
2.4
Table 2b. Two-tailed t-test for difference in the means of the
reversal potentials of the 1:3 and 3:1 α3 β2 groups. ( significance =
P<0.05).
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Mean Reversal Potentials (mV)
0
1:3

1:1

3:1

-5

mV

-10

-15

-20

-25

-30

Figure 13. Average reversal potentials for all groups; 1:3, 1:1, 3:1 (significance = P<0.05).
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Steady State Current Compared to Peak Current with Extended Agonist
Application (Forced Desensitization)
1:3
1:1
3:1
Mean (proportion of peak)
0.394
0.414
0.253
Standard Error
0.020
0.096
0.028
Median
0.394
0.368
0.234
Standard Deviation
0.029
0.192
0.068
Sample Variance
0.001
0.037
0.005
Range
0.041
0.441
0.161
Minimum
0.373
0.240
0.177
Maximum
0.414
0.681
0.338
Sum
0.787
1.656
1.517
Count
2
4
6
Table 3a. Column statistics for the steady state current compared to the peak
current from a 55s application of 10 mM ACh.

t-Test: Two-Sample Assuming Equal Variances
1:3
Mean (proportion of peak)
0.394
Variance
0.0008
Observations
2
Pooled Variance
0.004
Hypothesized Mean Difference
0
df
6
t Stat
2.719
P(T<=t) one-tail
0.017
t Critical one-tail
1.943
P(T<=t) two-tail
0.035
t Critical two-tail
2.447

3:1
0.253
0.0047
6

significant

Table 3b. Two-tailed t-test for difference in the means of the steady state current
compared to the peak current from a 55s application of 10 mM ACh.
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% of Peak After Decay in Forced Desensitization
0.6

*
0.5

0.4

0.3

0.2

0.1

0
1:3

1:1

3:1

Figure 14. Average steady state current compared to peak current in forced desensitization (*
indicates significance, P < 0.05).
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# of Exponents Used for Curve Fit
1:3
Mean
Standard Error
Median
Mode
Standard Deviation
Sample Variance
Range
Minimum
Maximum
Sum
Count

1.3
0.3
1
1
0.6
0.3
1
1
2
4
2

1:1
2.5
0.9
2
2
1.7
3
4
1
5
10
4

3:1
3.3
0.8
3
2
2.0
3.9
5
1
6
20
6

Table 4a. Column statistics for the # of exponents used to curve fit the forced
desensitization decay.

t-Test: Two-Sample Assuming Equal Variances
1:3
3:1
Mean
1.3
3.3
Variance
0.3
3.9
Observations
3
6
Pooled Variance
2.9
Hypothesized Mean
Difference
0
Df
7
t Stat
-1.7
P(T<=t) one-tail
0.07
t Critical one-tail
1.9
not
P(T<=t) two-tail
0.14 sig.
t Critical two-tail
2.4
Table 4b. Two-tailed t-test for difference in the means of the # of exponents used to
curve fit the forced desensitization decay.
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Mean # of Exponents Used to Curve Fit
4.5
4
3.5

# of Exponents

3
2.5
2
1.5
1
0.5
0
1:3

1:1

3:1

Figure 15. Average # of exponents used to fit the decay of the forced desensitization (significance =
P< 0.05).
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90-10% Decay Time
Mean (msec)
Standard Error
Median
Standard Deviation
Sample Variance
Range
Minimum
Maximum
Sum
Count

1:3
20074
5027
20074
7109
50536000
10053
15048
25101
40149
2

1:1
16647
675
17115
1350
1821800
2956
14701
17657
66589
4

3:1
13015
717
12696
1757
3086000
5176
11170
16347
78089
6

Table 5a. Column statistics for the decay times from 90% of the peak
current to 10% of the steady state current during forced desensitization
from 55s of 10 mM ACh.

t-Test: Two-Sample Assuming Equal Variances
1:3
3:1
Mean (msec)
20074
13015
Variance
50536000
3086000
Observations
2
6
Pooled Variance
10994000
Hypothesized Mean
Difference
0
Df
6
t Stat
2.6
P(T<=t) one-tail
0.02
t Critical one-tail
1.9
P(T<=t) two-tail
0.04 significant
t Critical two-tail
2.4
Table 5b. Two-tailed t-test for difference in the means of decay times
from 90% of the peak current to 10% of the steady state current
during forced desensitization from 55s of 10 mM ACh (significance =
P<0.05).
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90-10% Decay Time
30000

*
25000

Time (ms)

20000

15000

10000

5000

0
1:3

1:1

3:1

Figure 16. Average decay times from 90% of the peak current to 10% of the steady state current
during forced desensitization from 55s of 10 mM ACh (* indicates significance, P<0.05).
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Decay Tau1
Mean (msec)
Standard Error
Median
Standard
Deviation
Sample Variance
Range
Minimum
Maximum
Sum
Count

1:3
10687
77
10687

1:1
11824
2525
12106

3:1
11368
3318
9188

108
11744
153
10610
10760
21370
2

5050
25512438
9842
6620
16460
47300
4

8126
66038900
21807
5750
27550
68210
6

Table 6a. Column statistics for the decay tau from the forced
desensitization decay curves.

t-Test: Two-Sample Assuming Equal Variances
1:3
3:1
Mean (msec)
10687
11368
Variance
11744 66038900
Observations
2
6
Pooled Variance
55034374
Hypothesized Mean
Difference
0
Df
6
t Stat
-0.1
P(T<=t) one-tail
0.5
t Critical one-tail
2
P(T<=t) two-tail
0.9 not sig.
t Critical two-tail
2
Table 6b. Two-tailed t-test for difference in the mean decay tau
values from the forced desensitization decay curves.
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Mean Decay Tau1
16000
14000
12000

msec

10000
8000
6000
4000
2000
0
1:3

1:1

3:1

Figure 17. Average of the decay tau values from the forced desensitization decay
curves (significance = P<0.05).
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1:3
10-90% Rise
Time (msec)
Reversal
Potential (mV)
Steady State
Current (%)
# of
Exponents in
Decay Fit
90-10%
Decay Time
(msec)
Decay Tau
(msec)
EC50 [M]

222
-25
0.394

1.3

20074
10687
0.00013

3:1
98
-17
0.253

3.3

13015
11368
0.00025

1:1

Significance
(1:3, 3:1)

144

P=0.010,
significant

-18

P=0.09,
not sig.

0.414

P=0.035,
significant

2.5

P=0.14,
not sig.

16647

P=0.04,
significant

11824

P=0.9,
not sig.

0.00019

P=0.47,
not sig.

Table 7. Consolidated table of results. Values reported as averages. P values for two-tailed t-tests
between the 1:3 and 3:1 expression groups provided.
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DISCUSSION
Neuronal nAChRs are expressed throughout the PNS and CNS, and are involved
in a wide variety of physiological processes (Ortells 1995; Albuquerque, Pereira et al.
1996; Changeux, Bessis et al. 1996; Newhouse, Potter et al. 1997; Dani JA 2007). The
α3 subunit is widely expressed in the PNS, forming heteromeric receptors commonly
with the β4 subunit (Paterson and Nordberg 2000; Jensen, Frolund et al. 2005).
However, the α3 subunit has not been found to be widely expressed in the CNS. The
prevailing theory suggests that approximately 90% of neuronal nAChRs in the CNS are
α4β2 receptors, while the vast majority of the remaining nAChRs expressed in the CNS
are α7 homomers (Jensen, Frolund et al. 2005). Therefore, the α3β4 and the α4β2
receptors have been characterized quite well, due to the overwhelming evidence of
expression in the PNS and CNS respectively. However, the α3β2 receptor has not shown
much expression in the body overall, so it is relatively uncharacterized by comparison.
From the PCR data, it was surprising to find that; 1) the rat CA1 hippocampal
interneurons expressed α3 at such high levels, and 2) the α3β2 co-expression rate in the
hippocampus surpassed that of any other two-way subunit combination, including α4β2.
According to Welch 2008, the β2 subunit was expressed in 100% of the 106 whole
hippocampus tissue samples taken from Wistar rats ranging from 10 to 90 days in age,
while the α3 and α4 subunits were both expressed in over 90% of the same samples. The
range of expression of these subunits in the hippocampus is similarly high. However, the
relative expression levels of each subunit are quite different. The α4 subunit, though
widely expressed in the hippocampus, showed a relatively low level of expression
compared to all other subunits save the β3 subunit. The α3 subunit demonstrated a
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relative fold expression generally three times higher than the α4 subunit in the
hippocampus over the development of Wistar rats into adolescence. The β2 subunit
enjoyed the second highest level of expression of all subunits, just below the α5 subunit
(Welch 2008). Therefore, the α3 and β2 subunits were shown to be both widely and
highly expressed in the rat hippocampus throughout development. While the PCR data
presented in this thesis are taken specifically from individual CA1 hippocampal
interneurons and not the whole hippocampus, the data from the whole hippocampus
(Welch 2008) seem to support our findings extremely well. Because α4β2 containing
receptors have been shown to be widely expressed throughout the brain, there has been
an assumption that this subtype is one of the most prevalent in the hippocampus as well.
Our findings indicate that this assumption may be incorrect, with α3β2 containing
receptors demonstrating to be more predominant in the hippocampus (Wada, Wada et al.
1989; Alkondon and Albuquerque 1993; Jones and Yakel 1997; McQuiston and Madison
1999; Jensen, Frolund et al. 2005).
The co-expression rate of the α3 and β2 subunits in hippocampal interneurons was
not only the highest of all two-way subunit combinations in the hippocampal
interneurons, but it also proved to be 7.6% higher than expected (observed co-expression
43%, expected 35.4%), based on the individual expression rates of α3 and β2 (59.5% for
both α3 and β2 (i.e., 0.595 X 0.595 = 0.354 or 35.4% for the expected co-expression
rate). Moreover, 72% of interneurons that expressed α3 also expressed β2 and vice versa.
These data suggest a definite tendency for the α3 and β2 subunits to be co-expressed in
individual neurons. Due to the apparent prevalence of α3β2 receptors in hippocampal
interneurons and their lack of prevalence elsewhere in the body, the α3β2 receptors are an

45

ideal target of interest for research involving hippocampal pathologies where neuronal
nAChRs are implicated as being involved (i.e.- Alzheimer’s disease AD, schizophrenia,
etc.) (Court 2001; Woodruff-Pak DS 2002; Bourin, Ripoll et al. 2003).
Not only did our PCR data show the high rate of α3β2 co-expression in
hippocampal interneurons, but the relative stoichiometric expression ratios of α3:β2 were
measured as well. Of the 34 interneurons that co-expressed the α3 and β2 subunits, 15 of
them expressed α3 more than β2 by an average of 2.5 fold. The remaining 19 cells that
co-expressed the α3 and β2 subunits expressed the β2 subunit more than α3 by an average
of 3.3 fold. These data suggest that the 1:3 and 3:1 α3β2 expression groups might be
more physiologically relevant to future hippocampal studies. It also shows a slight
favoring of the receptors expressing more β2 than α3.
It is necessary to note that a plasmid containing the human α3 gene was combined
with a plasmid containing the rat β2 gene for expression in the oocytes used for voltage
clamp recordings. It is evident that the human α3 subunit readily associates with the rat
β2 subunit to form fully functional heteropentamers in terms of cationic selectivity,
current rectification, current conductance, agonist binding, and desensitization. Because
of the high homology between subunits (NCBI BLASTN pairwise alignment = 88%
identity for nucleotide sequences, BLASTP pairwise alignment = 95% identity for the
two protein sequences), we expected that the disparity in species would not inhibit the
formation of functional receptors. However, it would be interesting to see if rat α3β2
and/or human α3β2 receptors would produce the same kinetics, agonist affinity, and
agonist sensitivity as the chimeric combination we produced in our experiments.
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All three expression groups (1:3, 1:1, and 3:1 α3β2) produced functional
acetylcholine receptors on the oocyte membrane. The cells that were injected with 1:3
α3β2 subunit mRNA expressed receptors with significantly different kinetics than the
receptors expressed by the cells injected with α3β2 mRNA in the 3:1 ratio. The receptors
formed by the 1:3 α3β2 expression group demonstrated significantly higher values for
average 10-90% rise time, average 90-10% decay time during forced desensitization, and
average steady state current compared to peak current in forced desensitization than the
3:1 α3β2 expression group (Table 7). The forced desensitization decay data is
particularly interesting as it indicates a slower and lesser degree of desensitization in the
1:3 α3β2 expression group than the 3:1 group. The significantly different kinetics in the
receptors expressed by the 1:3 group and the 3:1 group indicate that the α3 and β2
subunits in these stoichiometric ratios produce different receptor populations.
The different receptors did not vary significantly in their reversal potentials. This
was expected because the pipette solution, bath solution, and temperature were kept
relatively constant throughout all of the experiments. All three expression groups did
display considerable inward negative current rectification (Figure 9). The receptors
expressed by the 1:3 α3β2 group also did not significantly differ from the receptors from
the 3:1 group with respect to decay tau and # exponents used to curve fit the decay in
forced desensitization. The similarity in decay tau suggests that the main component of
the decay during forced desensitization in the two receptor types is brought about by a
similar mechanism.
The # of exponents used to curve fit the decay in forced desensitization was not
significantly different between the distinct expression groups. The number of exponents
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used for the decay curve fit ranged from 1 to 6 exponents, while the average was 2.7. As
the # of exponents used to fit the decay curve increases, so does the complexity of the
curve. The multiple exponents used to fit the forced desensitization decay curves in our
experiments can employ one of two explanations. Different populations of receptors can
demonstrate different decay rates, or different populations of receptors can be expressed
within the same expression group. For example, while the 1:3 expression group would
favor expression of a higher number of β subunits than α subunits, they could form
pentamers with 1-α subunit and 4-β subunits or 2-α subunits and 3-β subunits. Different
populations of receptors within the same expression group may also be explained through
different specific subunit conformations. For example, though two receptors may both
contain two α3 subunits and three β2 subunits, one receptor may assemble to form a
functional channel with a specific conformation of α3α3β2β2β2, while a different
receptor may assemble in a specific conformation of α3β2α3β2β2.
The multiple exponents in the forced desensitization decay curve may also be
explained through multiple receptor states. In general, nAChRs are found in an active,
inactive, or desensitized state. However, contemporary models have proposed another
“resting” state or multiple desensitized states (Miyazawa, Fujiyoshi et al. 2003;
Giniatullin, Nistri et al. 2005; Gay and Yakel 2007). The receptors may be shifting
between desensitization states throughout the 55s ACh application to cause the complex
decay curve.
We established that the different expression groups produced distinct populations
of nAChRs based on their significantly different channel kinetics. Many previous
experiments have shown a shift in EC50 and agonist sensitivity with differential
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stoichiometric subunit expression (Zwart and Vijverberg 1998; Nelson, Kuryatov et al.
2003; Lopez-Hernandez, Sanchez-Padilla et al. 2004). In our experiments, there was no
significant difference between EC50 values of the different expression groups. However,
we noticed a definite pattern of change in EC50 values for the different groups as the
expression ratio of α3 and β2 changed. More than 120 currents at six different ACh
concentrations were normalized to peak currents and averaged to form the dose-response
curve of each expression group. The EC50 values were almost evenly-spaced between
expression groups, differing 60 µM between the 1:3 and 1:1 expression groups, and 56
µM between the 1:1 and 3:1 expression groups. The trend observed in our experiments
showed a greater sensitivity to ACh as the expression of the α3 subunit increased in
comparison to the expression of the β2 subunit. This observation seems to contradict the
pattern observed in other studies where an increase of β2 expression in relation to α4
increases the receptor’s sensitivity to ACh. This disparity may be due to specific
differences in the different subunits.
Future studies for further characterization of α3and β2 subunit containing
receptors could take many directions. Many different pharmacological studies can be
performed. For example, Luetje and Patrick used α3β2 and α2β2 receptors to show the
different relative sensitivities to application of ACh and nicotine (Luetje and Patrick
1991). They found that while application of ACh elicited larger currents in α3β2
receptors than α2β2 receptors, the opposite was true about nicotine. Equal application of
nicotine actually induced larger currents in α2β2 receptors than α3β2 receptors. This
could be further investigated to see if chronic exposure to nicotine increases or decreases
the expression of α3β2 receptors. Nelson et al. found that long-term exposure to nicotine
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up-regulates the expression of α4β2 receptors with the stoichiometric expression ratio of
2 α subunits to 3 β subunits and decreased all other stoichiometric expression (Nelson,
Kuryatov et al. 2003). Interestingly, they found that the 2:3 α4β2 receptor had the
highest sensitivity to ACh out of all the other stoichiometric formations.
Other nAChR agonists and antagonists may be used as well to compile a full
dose-response/EC50/IC50 profile for the different pharmacological agents (i.e.- nicotine,
cytisine, choline, epibatidine, 1,1-dimethyl-4-phenylpiperazinium, etc.) A useful
application of an antagonist study could possibly be found in α-conotoxin MII. This
toxin, isolated from the cocktail of toxins in cone snails, has been shown to specifically
block α3β2 and α6β2 receptors. Our PCR data showed absolutely no expression of the
α6 subunit in any of the CA1 hippocampal interneurons we analyzed. If α3β2 receptors
truly are prevalent and functional in rat hippocampal interneurons, a blockade of agonist
induced current would be observed with addition of α-conotoxin MII in an in vivo
voltage-clamp recording.
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